A study testing whether a GLP-1 medicine, semaglutide, can help people manage PCOS.

Recruiting now. Registry record last updated September 16, 2025.

Who can join: Children and teens 12 to 18, women only, have polycystic ovary syndrome (PCOS).
What you take: Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The study runs about 15 months.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Not ApplicableSponsor Nemours Children's ClinicDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 20

What this study is for

Primary condition: Polycystic Ovarian Syndrome in Adolescent Females. Also studied in: Obesity (Disorder).

Full scientific study title: Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome.

Who can join

Age12 to 18SexFemale

Children and teens 12 to 18, women only, have polycystic ovary syndrome (PCOS). A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Diagnosed with PCOS, by NIH criteria: oligomenorrhea (menstrual cycles \<21 or \>35 days) and hyperandrogenism (testosterone level or free androgen index (FAI) \> refence range for tanner stage) and in good overall health
Obesity (equal to or more than the 95th percentile)
Females ages 12 to 18 years, at least 2 years post-menarche
Participants has persistent symptoms of PCOS and obesity despite lifestyle modifications for at least 4 months.

Key exclusion criteria

Has abnormal thyroid function tests at Screening.
Has suspected or known Diabetes mellitus, impaired fasting glucose, or elevated hemoglobin A1c.
Has non-classic congenital adrenal hyperplasia.
Has hyperprolactinemia.
Has a known history or family history of medullary thyroid carcinoma or MEN2 and history of pancreatitis

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Florida1 site

Nemours Children's Clinic
Jacksonville, Florida
Camila Pereira-Eshraghi, MD. MS.1 + 904-408-7895camila.pereira-eshraghi@nemours.org

Follow this trial

We email you if NCT07169136 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: September 11, 2025. Expected completion: December 2026. Last updated on ClinicalTrials.gov: September 16, 2025.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.